Artiva Biotherapeutics, Common Stock Fundamentals
| ARTV Stock | 10.40 0.22 2.07% |
Artiva Biotherapeutics, Common fundamentals help investors to digest information that contributes to Artiva Biotherapeutics,'s financial success or failures. It also enables traders to predict the movement of Artiva Stock. The fundamental analysis module provides a way to measure Artiva Biotherapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Artiva Biotherapeutics, stock.
At this time, Artiva Biotherapeutics,'s Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 2.7 M in 2024, whereas Operating Income is likely to drop (32.2 M) in 2024. Artiva | Select Account or Indicator |
Artiva Biotherapeutics, Common Company Shares Owned By Insiders Analysis
Artiva Biotherapeutics,'s Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Artiva Biotherapeutics, Shares Owned By Insiders | 20.64 % |
Most of Artiva Biotherapeutics,'s fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artiva Biotherapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 20.64% of Artiva Biotherapeutics, Common are shares owned by insiders. This is 35.97% higher than that of the Biotechnology sector and 45.56% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is 104.56% lower than that of the firm.
Artiva Biotherapeutics, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Artiva Biotherapeutics,'s current stock value. Our valuation model uses many indicators to compare Artiva Biotherapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Artiva Biotherapeutics, competition to find correlations between indicators driving Artiva Biotherapeutics,'s intrinsic value. More Info.Artiva Biotherapeutics, Common is number one stock in return on equity category among its peers. It also is number one stock in operating margin category among its peers . At this time, Artiva Biotherapeutics,'s Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Artiva Biotherapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Artiva Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artiva Biotherapeutics,'s direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artiva Biotherapeutics, could also be used in its relative valuation, which is a method of valuing Artiva Biotherapeutics, by comparing valuation metrics of similar companies.Artiva Biotherapeutics, is currently under evaluation in shares owned by insiders category among its peers.
Artiva Fundamentals
| Return On Equity | -0.44 | ||||
| Operating Margin | (23.45) % | ||||
| Current Valuation | 120.95 M | ||||
| Shares Outstanding | 24.29 M | ||||
| Shares Owned By Insiders | 20.64 % | ||||
| Shares Owned By Institutions | 89.04 % | ||||
| Number Of Shares Shorted | 1.03 M | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 97.12 X | ||||
| Revenue | 33.49 M | ||||
| EBITDA | (28.41 M) | ||||
| Net Income | (28.72 M) | ||||
| Total Debt | 16.91 M | ||||
| Book Value Per Share | 8.28 X | ||||
| Cash Flow From Operations | (47.43 M) | ||||
| Short Ratio | 20.47 X | ||||
| Earnings Per Share | (2.48) X | ||||
| Target Price | 21.25 | ||||
| Number Of Employees | 82 | ||||
| Market Capitalization | 252.61 M | ||||
| Total Asset | 105.11 M | ||||
| Retained Earnings | (181.31 M) | ||||
| Working Capital | 67.59 M | ||||
| Net Asset | 105.11 M |
About Artiva Biotherapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artiva Biotherapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artiva Biotherapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artiva Biotherapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 12.5 M | 10 M | |
| Total Revenue | 33.5 M | 35.2 M | |
| Stock Based Compensation To Revenue | 0.21 | 0.20 | |
| Sales General And Administrative To Revenue | 0.42 | 0.39 | |
| Research And Ddevelopement To Revenue | 1.50 | 1.43 | |
| Capex To Revenue | 0.10 | 0.09 | |
| Revenue Per Share | 3.58 | 3.76 | |
| Ebit Per Revenue | (0.92) | (0.96) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.